Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of CMS121 and Phenylpiracetam hydrazide — mechanism, side effects, legal status, and pricing.
CMS121 is a non-peptide small-molecule quinoline, a synthetic analog of the natural flavonoid fisetin, developed to inhibit fatty acid synthase (FASN) and reduce lipid peroxidation in neuronal cells. It has completed a Phase 1 safety and pharmacokinetics trial in healthy volunteers (NCT05318040) but has no approved medical use and no published human efficacy data in Alzheimer's disease or any other condition. The compound is sold by research-chemical suppliers for laboratory use only; some direct-to-consumer vendors incorrectly market it as a "peptide" supplement despite its small-molecule structure.
Phenylpiracetam hydrazide is a non-peptide racetam-class small molecule — specifically a pyrrolidinone acetohydrazide in which the terminal carboxamide of phenylpiracetam (fonturacetam) is replaced by a carbohydrazide group. First synthesized in 1980 by a Russian medicinal-chemistry group screening 4-phenyl-2-pyrrolidinone derivatives for anticonvulsant activity, it has never been approved as a drug in any jurisdiction and has no human clinical trial data. The parent compound phenylpiracetam is explicitly listed on the WADA Prohibited List under S6.A (Non-Specified Stimulants); the hydrazide analog's own it is not on the WADA Prohibited List (only beta-2 agonists are prohibited, Category S3). It is sold by gray-market research-chemical vendors labeled 'not for human consumption.'
CMS121
Phenylpiracetam hydrazide
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
CMS121
Phenylpiracetam hydrazide
No pricing data yet.
Check Phenylpiracetam hydrazide prices →COA corpus from Disclosed Labs — independently tested batches only.
CMS121
3
COAs
99.1%
Avg purity
2
Labs
Phenylpiracetam hydrazide
2
COAs
99.4%
Avg purity
2
Labs
In APPswe/PS1dE9 double-transgenic mice (a model of Alzheimer's disease), dietary CMS121 (~34 mg/kg/day for 3 months starting at 9 months of age) normalized elevated hippocampal 4-HNE lipid-peroxidation adducts to wild-type levels, reduced 15-LOX2 and GFAP expression, and reversed cognitive deficits in Morris water maze testing to performance indistinguishable from wild-type mice. In vitro, CMS121 reduced iNOS, COX2, and TNF-α induction and blunted lipid-peroxidation increases in LPS-activated microglial cell cultures. A completed Phase 1 trial in approximately 100 healthy volunteers (NCT05318040) tested single oral doses up to 1800 mg and repeat doses up to 900 mg/day in young adults (600 mg/day in elderly subjects) for 7 days, reporting generally well-tolerated safety profiles with the majority of adverse events classified as mild; no serious adverse events were reported. Elderly subjects showed higher systemic exposure and longer terminal half-life than young adults, and fed-state exposure was approximately 50% higher than fasted with delayed absorption. No human efficacy data exist in Alzheimer's disease patients or any patient population.
Key references
No human clinical trials have been conducted; no ClinicalTrials.gov record or DrugBank entry exists. The sole preclinical finding is from the 1980 Glozman et al. synthesis paper: an ED<sub>50</sub> of approximately 310 mg/kg for seizure protection in a rodent electroshock assay (species, strain, sex, and route not fully recoverable from accessed sources). No published human toxicology, LD<sub>50</sub>, pharmacokinetics, or adverse-event data were located for this compound.
CMS121 and Phenylpiracetam hydrazide are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs